Mainz Biomed starts pioneering study of early cancer diagnosis!
Mainz Biomed starts pioneering study of early cancer diagnosis!
On April 28, 2025, Mainz gave Biomed N.V. A corporate update known for the first quarter. The focus was on the progress in relation to the FDA approval and the recent successes of the company. A central point was the admission of the first patient to the feasibility study Eaarly Detect 2, which evaluates an innovative intestinal cancer test.
This study, which is expected to include around 2,000 patients with average risk of colon cancer, uses a unique approach based on a portfolio of proprietary mRNA biomarker, a AI algorithm and a fit test. The aim of the study is to validate the results of earlier studies on the performance of the test and thus promote colon cancer prevention. Initial results are expected by the end of 2025, while the patient's recruitment is to be completed in the second half of 2025.
progress and research goals
The initiative for the Eaarly Detect 2 study was announced by Mainz Biomed. It aims to validate earlier research on the identification of advanced adenomas in a larger patient population. With the newly developed intestinal cancer test of the next generation, the ability of the study are examined to identify curable precancer -efficient colon polyps and early colon cancer with great accuracy.
The five new gene expression biomarkers, which were acquired from the University of Sherbrooke in Canada in 2022, are a central component of this study. Their performance, combined with the AI algorithm, is intended to further increase the diagnostic sensitivity and specificity in the detection of colon cancer in the early stage. In the future, Mainz is planning biomed, based on the results of the EAARLY DETECT 2 study, to complete the protocol for a US study called Reconaasense, which is scheduled to begin in 2026.
Future view and further developments
In addition to the ongoing studies, Mainz Biomed maintains a number of other molecular genetic diagnostic solutions. These include the Coloalert® intestinal cancer test and the pancreatic cancer test Pancalert. These tests represent a further step towards a more precise and early diagnosis of cancer, which is forecast for treatment and patients.With the combination of innovative biomarkers and advanced AI technology, Mainz Biomed pursues ambitious goals in the field of early cancer recognition and thus sets an important sign of future development in oncology.
For further information on the initiatives and progress of Mainz Biomed, you can find the complete reports at Wallstreet online href = "https://mainzbiomed.com/mainz-biomed-initiert-klinische-studie-zur-evaluier-der-destes-te-der-nachsten-zur-zur-wer--adenomen-iner-enomen-iner-grose-population/"> Mainz biomed read.
These comprehensive approaches and the resulting progress are a sign of hope for the prevention and early detection of colon cancer, which is a significant health threat worldwide.
| Details | |
|---|---|
| Quellen | |